EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2025-04-30
Management highlights
• Strong third quarter results with 12% y-o-y revenue growth, driven by developed and emerging markets. • Adjusted EBITDA was $6 million compared to $1.1 million a year ago, driven by volume, pricing, and operational improvements. • Book-to-bill was over 1.2x, indicating healthy customer demand. • Service revenue grew 9% y-o-y, expected to be a growth engine. • Implemented tariff mitigation actions like foreign trade zone establishment, duty drawback, secondary domestic sourcing, and working with China JV for tariff exemption. • Net inventory balance down $2 million from prior quarter due to lean inventory management.
Segment performance
For the third quarter, revenue grew 12% year-over-year. Product revenue was up 16% versus the prior year, driven by strong demand across the portfolio. Service revenue grew by 9% year-over-year. The service business represented approximately 49% of revenue and 59% of gross margin in the quarter.
Guidance
• Q4 revenues expected in the range of $121 million to $129 million and adjusted EBITDA in the range of $9.5 million to $12 million. • Maintained adjusted EBITDA guidance for fiscal year ‘25 in the range of $28.5 million to $31 million.
Risks
• Potential negative impact of $10 million to $15 million in Q4 revenue due to tariffs on product sales in China. • Uncertainty around tariff dynamics and geopolitical situation affecting global operations.
Q&A highlights
Q: Brooks O’Neil asked about the impact of deferred China adjusted EBITDA in the quarter.
A: Ali Pervaiz responded that product margins were affected by higher margin deferral on China, but overall product margins hover around 31% which is in line with goals.
Q: Brooks O’Neil asked about the impact in markets like India and South America compared to China.
A: Suzanne Winter said China impact is the highest, but they see strength in EMEA including India, non-China APAC is performing strong.
Q: Marie Thibault asked about China tariff exemption scenarios.
A: Suzanne Winter stated they are working closely with the China JV for a medical device exemption but lack clarity on timing.
Q: Marie Thibault asked about shipping quickly if exemption is granted.
A: Suzanne Winter replied it could be relatively quick.
Q: Jason Wittes asked about resource diversion from China to emerging markets.
A: Suzanne Winter mentioned taking advantage of opportunities in developed markets like UK stimulus and seeing strength in non-China APAC with strong orders in various countries.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-0.01 | $-0.05 | +80.0% | $-0.06 |
| Revenue | $113.2M | $123.8M | -8.5% | $101.1M |
Transcript
April 30, 2025Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.